Compositions and methods for the therapy and diagnosis of prostate cancer

An isolated polynucleotide comprising a sequence selected from the group consisting of:

• (a) sequences provided in SEQ ID NOs:
• 944-945, 948, 967, 969-976, 991, 993-1002, 1004, 1006-1007, 1010,1013-1019, 1021,1023-1027;
• (b) complements of the sequences provided in SEQ ID NOs:
• 944-945, 948, 967, 969-976, 991, 993-1002, 1004, 1006-1007, 1010, 1013-1019, 1021, 1023-1027;
• (c) sequences consisting of at least 20 contiguous residues of a sequence provided in SEQ ID NOs:
• 944-945, 948, 967, 969-976, 991, 993-1002, 1004, 1006-1007, 1010, 1013-1019, 1021, 1023-1027;
• (d) sequences that hybridize to a sequence provided in SEQ ID NOs:
• 944-945, 948, 967, 969-976, 991, 993-1002,1004, 1006-1007, 1010, 1013-1019, 1021, 1023-1027, under highly stringent conditions;
• (e) sequences having at least 75% identity to a sequence of SEQ ID NOs:
• 944-945, 948, 967, 969-976, 991, 993-1002, 1004, 1006-1007, 1010, 1013-1019, 1021, 1023-1027;
• (f) sequences having at least 90% identity to a sequence of SEQ ID NOs:
• 944-945, 948, 967, 969-976, 991, 993-1002, 1004, 1006-1007, 1010, 1013-1019,1021, 1023-1027;
• and
• (g) degenerate variants of a sequence provided in SEQ ID NOs:
• 944-945, 948, 967, 969-976, 991, 993-1002, 1004, 1006-1007,1010, 1013-1019, 1021, 1023-1027.